Inclisiran patent expiry?

Inclisiran (brand Leqvio) is an siRNA medicine by Alnylam for lowering LDL-cholesterol.

Patents / exclusivity: what “expiry” usually means

Patent expiry for a drug depends on jurisdiction (US/EU/UK/etc.) and on:

• the core compound patent term,
• secondary patents (formulations, methods of use),
• and regulatory exclusivity (e.g., EU SPCs/UK SPCs, data/market exclusivities).

Current practical view (high level)

• The earliest meaningful exclusivity/patent protection for inclisiran is generally expected to run into the late 2020s to around 2030 in many markets, with exact dates varying by country and whether an SPC (Supplementary Protection Certificate) is granted.
• Some later “secondary” patents may extend protection modestly after the first patent term, but these vary widely.

To give you the exact expiry date

Can you tell me:

1. Which country/region you care about (US, EU, UK, etc.)?
2. Whether you mean patent expiry specifically, or regulatory exclusivity/SPC?

If you share the country (or paste a link to a patent listing you’re looking at), I can help interpret it and summarize the likely “first generic/biosimilar entry” window.